CANMAb (Trastuzumab) for Injection (r-DNA Origin)

CANMAb is a brand-name prescription drug that’s FDA-approved to treat • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer). Brand Name: CANMAb (Trastuzumab) for Injection (r-DNA Origin).

CANMAb (Trastuzumab) for Injection In India and Overseas
CANMAb (Trastuzumab) for Injection (r-DNA Origin)

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

CANMAb (Trastuzumab) for Injection (r-DNA Origin)

Trastuzumab is approved to treat: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer).

CANMAb is a HER2/neu receptor antagonist indicated for:
• the treatment of Metastatic Breast Cancer (MBC).
• the treatment of Early Breast Cancer (EBC).
• the treatment of EMetastatic Gastric Cancer (MGC).

A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2 positive. It is also being studied in the treatment of other types of cancer. Trastuzumab binds to a protein called HER2, which is found on some cancer cells. This may help the immune system kill cancer cells. Trastuzumab is a type of monoclonal antibody and a type of HER2 receptor antagonist. Also called Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera. Trastuzumab is approved to be used alone or with other drugs to treat: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer)
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/trastuzumab

Drug (Brand / Generic): CANMAb / Trastuzumab
Current Indications: • Breast cancer that is HER2 positive (HER2+). & • Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma
Marketed by:: Biocon Biologics India Limited
Approval Date: 1998

Available as (Form & Strength): Reconstituted solutions made with bacteriostatic water for injection, as supplied, are stable (physico-chemically and 0 0 microbiologically) for 28 days, when refrigerated at 2 C to 8 C. The reconstituted solution is suitable for multiple uses, as it contains preservative. Discard any remaining reconstituted solution after 28 days. Do not freeze the reconstituted solution.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.